Zydus Lifesciences jumps after its arm receives tentative approval from USFDA for Roflumilast Tablets

Zydus Lifesciences is currently trading at Rs. 416.30, up by 4.90 points or 1.19% from its previous closing of Rs. 411.40 on the BSE.

Zydus Lifesciences
Zydus Lifesciences

The scrip opened at Rs. 411.05 and has touched a high and low of Rs. 416.90 and Rs. 409.00 respectively. So far 9982 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 545.00 on 18-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.

Last one week high and low of the scrip stood at Rs. 426.80 and Rs. 409.00 respectively. The current market cap of the company is Rs. 42117.81 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 15.53% and 9.49% respectively.

Zydus Lifesciences’ U.S. subsidiary–Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market Roflumilast Tablets USP, 250 mcg (USRLD: Daliresp).

Roflumilast Tablets are indicated as a treatment to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.

Roflumilast Tablets had annual sales of $248 million in the United States according to IQVIA data (IQVIA MAT Aug 2022).

The group now has 326 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Leave a Comment